N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Recent data have suggested that monocyte oxidative burst defect is associated with the
development of infection in patients with severe alcoholic hepatitis. One report found
reduced 28 day mortality in patients treated with N-acetylcysteine combined with prednisolone
when compared to prednisolone alone. The current study seeks to reveal whether the mechanism
by which NAC reduces susceptibility to infection is through improvement of phagocyte
oxidative burst.